| miR-135b |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Resistant |
High |
22045191 |
|
| miR-140 |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Resistant |
High |
22045191 |
|
| miR-141 |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-197 |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-200b |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-200c |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-205 |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-224 |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-301a |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-34c |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-518f* |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-628 |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-636 |
Erlotinib |
epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)) |
Sensitive |
High |
22045191 |
|
| miR-205 |
Erlotinib |
melanoma |
Sensitive |
Low |
23447575 |
|
| miR-146a |
Erlotinib |
non-small cell lung cancer |
Sensitive |
Low |
23555954 |
|
| miR-135b |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-139 |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-141 |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-155 |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-200a |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-200b |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-200c |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-429 |
Erlotinib |
pancreatic adenocarcinoma |
Sensitive |
High |
23918833 |
|
| miR-200c |
Erlotinib |
non-small cell lung cancer |
Resistant |
Low |
23963283 |
|
| miR-21 |
Erlotinib |
non-small cell lung cancer |
Sensitive |
Low |
23963283 |
|
| miR-34a |
Erlotinib |
head and neck cancer |
Sensitive |
Low |
24026012 |
|
| let-7c |
Erlotinib |
non-small cell lung cancer |
Sensitive |
Low |
24199791 |
|
| miR-200b |
Erlotinib |
non-small cell lung cancer |
Sensitive |
Low |
24199791 |
|
| miR-30b |
Erlotinib |
non-small cell lung cancer |
Associated |
Low |
24286402 |
|
| miR-34a |
Erlotinib |
non-small cell lung cancer |
Sensitive |
Low |
24551227 |
|
| miR-200 |
Erlotinib |
cancer |
Sensitive |
Low |
24830724 |
|
| miR-497 |
Erlotinib |
pancreatic cancer |
Sensitive |
Low |
25149530 |
|
